Vaxcyte, Inc. (PCVX) · Oct 5, 2026 · Other events
Above the bar — All primary endpoints met; 4 of 4 unique-serotype comparisons achieved superiority
Vaxcyte’s OPUS-1 Phase 3 trial met every primary endpoint for VAX-31, supporting the BLA path, though two PCV21 comparisons missed the stricter bar.
Vaxcyte is a clinical-stage vaccine company trying to turn its broad-spectrum VAX-31 pneumococcal vaccine into a commercial product, with three adult Phase 3 trials feeding a planned BLA. OPUS-1 was expected in the fourth quarter of 2026, so the timing was largely anticipated; the new information is how cleanly the pivotal trial cleared its prespecified tests.
The pivotal efficacy hurdle was cleared cleanly. In adults aged 50 and older, VAX-31 met noninferiority across all 28 serotypes shared with PCV20 and/or PCV21, while the three unique serotypes plus cross-reactive 20B met the superiority criterion. That is better than a merely adequate readout: it supports the central product claim that VAX-31 can broaden coverage without sacrificing immune response.
Safety did not introduce a tradeoff. The 4,047-subject study found a safety profile similar to PCV20 and PCV21, with no vaccine-related serious adverse events and no discontinuations due to adverse events. 〔0〕 For a vaccine seeking broad use in older adults, that keeps the regulatory story straightforward rather than forcing Vaxcyte to defend added reactogenicity.
The main qualification is the PCV21 comparison, not the primary endpoint result. VAX-31 met the prespecified noninferiority bar for all 20 shared PCV20 serotypes but for only 17 of 19 shared PCV21 serotypes; serotypes 3 and 12F missed the stricter >0.667 threshold, though both cleared the historical >0.5 threshold. That matters because Vaxcyte itself expects FDA review to focus particularly on the PCV21 comparison, given those serotypes’ relevance to current U.S. disease coverage. It is a manageable caveat, but it prevents the result from being an unqualified win on every comparator-specific measure.
The filing advances Vaxcyte from clinical validation toward regulatory execution. OPUS-1 is described as the cornerstone of the planned BLA, but OPUS-2, OPUS-3, manufacturing consistency work and FDA review still stand between this topline result and approval. The company expects OPUS-2 and OPUS-3 results in the first half of 2027 and a planned BLA submission in the first half of 2028. 〔1〕
Bottom line: This is a genuinely strong clinical readout versus the prespecified bar and materially strengthens the VAX-31 approval case. The two PCV21 misses are the key detail to carry forward, but they do not overturn the primary-endpoint success or the planned regulatory path.
OPUS-2 and OPUS-3 results, first half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.